- Home
- ORGN vs IPHA Comparison
ORGN vs IPHA Comparison
Compare ORGN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGN
- IPHA
- Stock Information
- Founded
- ORGN 2008
- IPHA 1999
- Country
- ORGN United States
- IPHA France
- Employees
- ORGN N/A
- IPHA N/A
- Industry
- ORGN Major Chemicals
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- ORGN Industrials
- IPHA Health Care
- Exchange
- ORGN Nasdaq
- IPHA Nasdaq
- Market Cap
- ORGN 149.2M
- IPHA 160.1M
- IPO Year
- ORGN N/A
- IPHA 2019
- Fundamental
- Price
- ORGN $0.66
- IPHA $1.94
- Analyst Decision
- ORGN Strong Buy
- IPHA Strong Buy
- Analyst Count
- ORGN 1
- IPHA 1
- Target Price
- ORGN $3.00
- IPHA $11.50
- AVG Volume (30 Days)
- ORGN 1.1M
- IPHA 15.1K
- Earning Date
- ORGN 03-13-2025
- IPHA 03-27-2025
- Dividend Yield
- ORGN N/A
- IPHA N/A
- EPS Growth
- ORGN N/A
- IPHA N/A
- EPS
- ORGN N/A
- IPHA N/A
- Revenue
- ORGN $31,282,000.00
- IPHA $20,831,349.00
- Revenue This Year
- ORGN $83.02
- IPHA $220.44
- Revenue Next Year
- ORGN $24.18
- IPHA $81.85
- P/E Ratio
- ORGN N/A
- IPHA N/A
- Revenue Growth
- ORGN 8.60
- IPHA N/A
- 52 Week Low
- ORGN $0.49
- IPHA $1.29
- 52 Week High
- ORGN $1.90
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- ORGN 29.95
- IPHA 39.67
- Support Level
- ORGN $0.64
- IPHA $1.77
- Resistance Level
- ORGN $0.77
- IPHA $2.03
- Average True Range (ATR)
- ORGN 0.05
- IPHA 0.09
- MACD
- ORGN -0.01
- IPHA -0.02
- Stochastic Oscillator
- ORGN 9.08
- IPHA 3.57
Stock Price Comparison Chart: ORGN vs IPHA
About ORGN Origin Materials Inc.
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.